Member Info for B2HS2L

Kitzie -
NCYT only announced SNPsig range of tests in Feb 2021.

Paris, France and Camberley, UK - 2 February 2021 - Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces the launch of a new and innovative portfolio of assays (under the brand name SNPsig®) to aid the diagnosis of the new variants of SARS-CoV-2.

Need to look at half year results for both companies perhaps.

Leicesterboy -
Googling "Oxford Nanopore tools have been used for 1/5th of all Covid Sequencing" produces no match.
Can you assist with a link please?

Stephenson Harwood Life Sciences team - These guys should be well versed in the DHSC dispute details if nothing else

https://www.thelifescienceshub.com/expertise/intellectual-property

Novacyt S.A.
Advised Novacyt on acquiring the entire share capital of IT-IS International Ltd, a profitable diagnostic instrument development and manufacturing company, for an initial cash consideration of £10.1 million. IT-IS is the exclusive manufacturer of Novacyt’s q16 and q32 rapid polymerase chain reaction (PCR) instruments and the deal was vital to securing key IP for Novacyt's rapid-PCR instruments.

+++
https://www.thelifescienceshub.com/expertise/ecm-ipos-and-secondary-financings

Novacyt SA
Advised French Euronext Growth, Paris-listed diagnostics company Novacyt on its dual listing admission to AIM and associated placing with Stifel as broker. The transaction was the first Paris-AIM dual listing. We have since advised Novacyt in relation to various matters including M&A and most recently, the contractual arrangements behind the rollout of its highly successful COVID-19 test.

+++
https://www.thelifescienceshub.com/expertise/tech-ops-and-business-support

Novacyt
We acted for Novacyt S.A. in relation to the supply of COVID-19 PCR test kits to the Department of Health and Social Care.

Poidster, -
1701 q16's
1773 q32's
Commencement date 10.08.2021
Expirey date 31.03.2022

Allowing for a linear supply of instruments throughout the contract:
10.08.21 to 31.03.22 = 233 days
aprox
8 q16's / day
8 q32's / day

But IMO it is possible a higher instrument delivery schedule will be required at start of contract, tailing off toward the end.

Nothing reads like a porky post.
Full of repetition and ramping.
No point in complaining, it's in his DNA - or do I mean RNA.
Thankfully it's not long before new posters twig on.

Porky - Re your 03:34 post - item 2

"The SNPsig® EscapePLEX SARS-CoV-2, is the first in the market to detect the following mutations:
•Alpha •Beta •Gamma •Delta •Delta Plus
And as Assays run on ANY hardware not just Novacyt's own, its no wonder Major labs around the world are buying Promate."
+++

17.05.2021 RNS extracts * 3:

· SNPsig® SARS-CoV-2 (E484K) Easy is a research-use-only, streamlined workflow solution for the detection of SARS-CoV-2 variants carrying the E484K escape mutation for use with the Company's q32 rapid-PCR instrument. This assay comes with pre-filled cassettes and includes only one pipetting step to decrease operator complexity and improve cycle times.

About SNPsig® SARS-CoV-2 (E484K) Easy
SNPsig® SARS-CoV-2 (E484K) Easy is a rapid direct solution based on the Company's simplified PROmate workflow, to detect the E484K mutation in SARS-CoV-2 variants in less than 90 minutes using the Company's q32 instrument. [q32 only ]

About the E484K mutation
The E484K mutation has appeared independently in several VoC, indicating an evolutionary advantage for SARS-CoV-2. Multiple studies have shown an association with reduced antibody neutralisation in both natural and vaccine-elicited human sera. Early detection of the E484K mutation is critical to ensure a rapid public health response.

+++

https://genesig.com/assets/files/mm142_issue_2_snpsig_sars_cov_2_e484k_easy.pdf refers

To date, this is the only SNP-sig test to be based on the PROmate workflow.

Porky, - Did a bit of digging wrt James McCarthy's experience, and I would not agree he has 'significant stateside experience'.

However, that description fits GM's experience well.

Anthony Dyer no longer has the role of Chief Corporate Development Officer (CCDO).

He has not been replaced, so the CCDO role disappears, - or does it?

I have no basis for what follows, but am asking myself whether stars are aligning here.

Post retirement GM might perform the CCDO role at the behest and with the willing involvement of DA and Guillermo Raimondo.

source - https://www.linkedin.com/in/guillermo-raimondo/

About Guillermo
As an experienced international executive with a unique combination of people and project management, business and result orientation, and high strategic orientation and execution capabilities, I am always seeking to excel individual, team and business performance.
My background and success in full blown P&L operations in a variety of businesses (commoditized fast-moving products to disruptive and innovative solutions), markets and scale of organizations (country, regional, and global operations) allows me to adapt and drive change according to business needs.
I’m being recognized for creating and executing processes and procedures that improve business operations. I also have a strong ability to guide tasks from concept to completion ensuring on-time, on-budget, and on-target results.
As a leader I focus on coaching, developing and leading individuals and teams to achieve and beat established objectives and standards.

+++

RNS - 29.01.2021 -
"Novacyt has also appointed Guillermo Raimondo to the newly formed, non-Board role of Chief Commercial Officer to lead the Company's global commercial operations.
Previously, Guillermo had a successful career at Siemens Healthineers where his last two roles were as Regional President and more recently Executive Vice President Global Marketing & Sales"

+++

So I don't see Guillermo Raimondo being a natural deal maker, nor being hired to be so, but I do see GM being successful at filling that role, as he has done many times in USA before.

IMO GM might be the person with sufficient experience and contacts, who may try to create the deals and joint ventures our company requires in USA or elsewhere, ie become our next CCDO whilst also being semi-retired.

Yes AFAIK GM is retiring, but an opportunity exists for DA and GM and to generate significant synergies with receptive CEO's in (primarily) USA.

https://novacyt.com/general-meetings/#1631089012449-20a94337-4ba5

Ahem, - With a really good Sales & Marketing specialist arriving, and with Ajan Reginald still revving the R&D engine, I'm counting on a faster (three year) sp ascent, as we have so few shares in issue.

30.08.2021

https://www.genomeweb.com/pcr/sars-cov-2-delta-variant-pcr-could-help-surveillance-efforts-developers-say#.YTQNMo5KhhF

Too much to post here, and doesn't mention Novacyt, but opens a door on USA surveillance efforts.

2/2
The causes of myeloma are not fully understood but it is believed to be caused by an interaction of both genetic and environmental factors.
Key facts
• There are approximately 5,700 people diagnosed with myeloma every year in the UK
• There are approximately 17,600 people living with myeloma in the UK at any one time
• Myeloma accounts for 15% of blood cancers and 2% of cancers generally
• Myeloma mostly affects people aged 65 and over but it has been diagnosed in people as young as 20.

+++
Dolon Ltd Strategic Advisory Board Member.
RARE Knowledge | Strategic Thinking | Collaborative Partnerships. Pharmaceuticals London

Headquartered in London, Dolon is a small, dynamic, fast-growing company with a strong reputation and a bright future.
Our skilled consultants, based throughout Europe, are ready to share their wealth of knowledge to support you in the rare disease market.

From LinkedIn:
Dolon is an international market access consultancy that specialises in rare and severe diseases.
We have an exciting international client base of fast-growing companies with innovative and important portfolios of orphan drugs.
Working in close partnership with Global and Regional teams, we help them define and communicate the value of their products to payers, policymakers and society.

We are constantly updating our knowledge of reimbursement pathways and payer requirements.
Our multi-stakeholder network of payers, rare disease experts, industry associations and patient organisations allows us a nuanced understanding of the decision making process and a bird’s eye view on the evolving environment of orphan diseases.
We use our unique perspective to inform our clients’ strategic thinking about rare disease market access, and to help them prepare for pricing and reimbursement negotiations.
We provide services in the following areas:

• Value Strategy & Communication
• Pricing & Reimbursement
• Market Access Policy

++++

source video: https://www.youtube.com/watch?v=ADcZzV9TyA0 (1:20)

"I'm a through and through marketeer, sales / market access guy."

"I'm really grass roots in the commercial arena, since I was first in sales."

"Selling medicinal drugs for nearly 25 years".

1/2

source - https://www.amrytpharma.com/about-us/our-team/
David Allmond joined Amryt Pharma as Chief Commercial Officer in March 2017. Prior to joining Amryt, he was President Europe, Middle East and Africa (EMEA) at Aegerion Pharmaceuticals, where he was responsible for the commercialisation of Lojuxta (lomitapide), a treatment for Homozygous Familial Hypercholesterolemia (HoFH) recently in-licensed by Amryt Pharma. Mr. Allmond was previously Corporate Vice President of Global Marketing at Celgene, where he played a pivotal role in defining strategy for in-line brands, lifecycle/pipeline prioritisation and commercial direction for business development. He was also responsible for EMEA marketing and market access.

Amryt buys Aegerion via bankruptcy, adding sales to support
https://www.fiercebiotech.com/biotech/amryt-buys-aegerion-via-bankruptcy-adding-sales-to-support-r-d
25 Sept 2019 — Amryt Pharma has completed the acquisition of Aegerion Pharmaceuticals. ... Last year, the products generated sales of $136.5 million.

source: https://www.crunchbase.com/person/david-allmond
David Allmond has 2 current jobs as CCO at Amryt Pharma and President, EMEA at Aegerion Pharmaceuticals

source LinkedIn:
Amryt Pharma - Chief Business Officer - Sept 2020 to present.
Leading on Corporate strategy development, business development, global marketing, global market access & global business planning and analysis.

+++++
David Allmond is a Non Executive Director of the Board at Myeloma UK.
LinkedIn says he stopped filling that role in March 2020.

Companies house (checked 20.08.2021) states:
MYELOMA UK

ALLMOND, David
Correspondence address
22 Logie Mill, Logie Mill, Beaverbank Business Park, Edinburgh, Scotland, EH7 4HG
Role *ACTIVE* Director
Date of birth February 1970
Appointed on 5 February 2013
Nationality British
Country of residence United Kingdom
Occupation Marketing

Most of the complications and symptoms of myeloma are caused by a build-up of the abnormal plasma cells (often called myeloma cells) in the bone marrow and the
presence of paraprotein in the body. Common problems in myeloma include bone pain, bone fractures, fatigue, frequent or recurrent infection and kidney damage.
Myeloma is highly treatable in the majority of cases. Treatment is aimed at controlling the disease, relieving the complications and symptoms it causes, and extending
and improving the quality of life. Treatment for myeloma is often most effective when two or more drugs with different but complementary mechanisms of action are given together.
Treatment is usually given over a number of weeks and may or may not be followed by a rest period. This pattern constitutes one cycle of treatment and a series of treatment
cycles is referred to as a course or line of treatment. While there are many effective treatments for myeloma, unfortunately it is currently incurable.

Thanks for the news mavs -
One of the marketing job descriptions :
https://novacyt.com/wp-content/uploads/2021/08/Advert-Market-Research-Analyst.pdf

Main duties and responsibilities
• Works under the direction of a marketing director to understand the marketing team’s short term and
long term goals and objectives
• Coordinate the delivery of market opportunity data sets to support upstream and downstream
marketing activities
• Coordinate the collection, presentation and revision of competitive data, both from strategic and
product perspective
• Present the collected data in a manner that is both understood and valuable to the key stakeholders
looking to utilise it
• Support the marketing team in consideration and submission of long term strategic decision making
• Support the comprehension of the annual marketing plan
• Use metrics to help Novacyt understand its market footprint and product viability success, and where
improvements can be made
• Collect data on consumers, competitors, identify market trends, pricing/business models, sales and
methods of operation and consolidate information into actionable items, reports and presentations
• Understand business objectives and design surveys to discover prospective customers’ preferences
• Perform valid and reliable market research SWOT analysis
• Interpret data, formulate reports and make recommendations
• Use online market research and catalogue findings to databases
• Evaluate program methodology and key data to ensure that data on the releases are accurate and the
angle of the release is correct
• Remain fully informed on market trends, other parties researches and implement best practices

I would be surprised if David Allmond had not written this job description. - IMO this is why:

https://www.youtube.com/watch?v=ADcZzV9TyA0

In this presentation at 1:20 - David Allmond mentions :

"I'm a through and through marketeer, sales / market access guy."

"I'm really grass roots in the commercial arena, since I was first in sales."

"Selling drugs for nearly 25 years".

I believe this is how he see's himself.

++++

So as a change of CEO can be seen as a change in the companies fundamentals, we can expect to loose a market savy scientist with 12 years+ experience as a CEO of Lab21/Novacyt, who definitely understands tech, with a flair for deals, partnerships and acquiring companies.
In his place we will get a sales and marketing specialist (with cancer experience), with no CEO experience who will be relying on his newly built top management team members for technical leadership surrounding qPCR use, genomic sequencing and any expertise in transplants.

+++

Our Marketeers could do with a new focus, and IMO they will get that.
I'm excited about what DA will bring, sorry to see GM go.

Whatnonewsyet -
Good post, and I agree with you.
However, - another way of looking at the IT-IS acquisition is thus:

IT-IS were busy selling Mygo products to labs worldwide, whilst also selling more and more instruments to Novacyt branded as q16 / q32.

IT-IS increased their output to try to keep up with demand after C-19 started in q1 last year.

In order for GM to service contracts he was negotiating (with DHSC ) and selling to Germany, USA and Middle East etc, he needed security of supply and access to more and more instruments.

Novacyt did not make instruments, they just specialised in making good assays to be used on the IT-IS built q16 / q32 and the other manufacturers platforms they tested their assays on. So I doubt GM wanted to go into UK based instrument manufacture.

IMO it became clear to GM that IT-IS, were not capable of meeting his orders for further instruments, so Novacyt were going to have to step in and buy the manufacturer, or start using other PCR platforms.

If you are starting to sell instruments for Point of Care applications outside a lab, then the q16/q32 platform was an excellent choice, thus confirming the original decision to use q16/q32.

The 15.10.2020 RNS contains the following relevant quotes:

1 With the acquisition of IT-IS, the Company is well positioned to address this drive towards rapid, decentralised testing and deliver additional growth opportunities.

2 As a result of this acquisition, Novacyt will become a diagnostic platform instrument and reagent manufacturer and will significantly increase the manufacturing capability of IT-IS to manage the expected demand for its q16 and q32 PCR instruments. As a result of higher manufacturing volume, the Company expects to reduce its cost of goods and therefore improve the gross margin of its instrument sales.
+++
If a competitor had bought IT-IS, they would have been in a position to starve Novacyt of the instruments crucial to the companies Point of Care applications, so IMO at least half the decision to purchase IT-IS was to secure the supply of instruments, and to ensure Novacyt orders got priority should large orders land after purchasing IT-IS.

JM2c

Great response kaeren, - anyone feel like adding to the stew, then we will have a list of pressing items.
We may be able to discuss a 100 day plan of action for these items via a AGM question, (it's favoured for new bosses in America), so that it is evident what changes are made in that timescale.

Chard -
DHSC resolution of any sort will result in a step change in share price the minute it is announced.
How big that change is depends on a number of things, - but you won't be feeling so bad afterwards.
- Chin up, can't say when that might be.

bobminor / kaeren
If t'were me I would want to review the current 5 year plan and strategy to meet targets.
I'd want skin in the game ASAP
Overhauling Marketing would be high on the list, and a complete debrief on DHSC issues.
Reviewing the need for two exchanges is necessary, and the benefits , - real or imagined - of NASDAQ membership.
That last one could take years, so an early start would be welcome.

Porky, - sometimes an error creeps in with a post and it becomes by default true from then on for other posters.
Jon Coffey was a commercial director at Abbott when he left.
He has been appointed as UK and Ireland country manager at NCYT, a job he did for Abbott in a previous position.
I note he left Abbott in April 2021.

Jon Coffey's new NCYT role is UK&I country manager

This is his previous relevant experience at Abbott:
Country Manager
Full-time
Dates Employed Oct 2012 – Oct 2018
Employment Duration6 yrs 1 month
Location United Kingdom
Lead Abbott Molecular Division in UK & Ireland and Nordics (2017- 18).
Primarily focusing on clinical diagnostics solutions specifically in infectious disease, oncology and transplant sectors.

Grew revenues year on years and established key collaborations with major hospitals to develop and commercialise new integrated workflows and patient pathways
++++
Bullseye!

Thanks for the link Fruitsnveg.

I stumbled across this story also on the same site, apologies if previously posted:

01.09.2021 -
Study: Monoclonal Antibody Treatment Combination Reduces Hospitalization Among High-Risk Patients with COVID-19

https://www.pharmacytimes.com/view/study-monoclonal-antibody-treatment-combination-reduces-hospitalization-among-high-risk-patients-with-covid-19

"The findings showed that at day 14, 1.3% of the treated group was in the hospital"
"At day 21, only 1.3% of those treated were hospitalized"
"Additionally, at the end of 28 days, 1.6% of those treated were hospitalized"

So none of the treated group were leaving hospital? - confused.